Literature DB >> 1600599

In vivo distribution of [11C]-busulfan in cynomolgus monkey and in the brain of a human patient.

M Hassan1, G Oberg, K Ericson, H Ehrsson, L Eriksson, M Ingvar, S Stone-Elander, J O Thorell, B Smedmyr, N Warne.   

Abstract

The in vivo distribution of the antileukemic agent busulfan labeled with the positron-emitting radionuclide carbon 11 was investigated in cynomolgus monkeys and in a human patient using positron emission tomography. After i.v. injection of the radiotracer, its regional uptake was monitored for about 1 h in the monkey's body and, in a separate experiment, in the monkey's brain. The concentration of radioactivity in the liver, which showed the highest levels of all the organs scanned, increased throughout the experiment and was 9-fold that in the brain at the end of the experiment. [11C]-Busulfan rapidly crossed the blood-brain barrier. The radioactivity peaked in both the cortex and the white matter showing a ratio of 1.25, at 3 min but declined quickly to yield a ratio of approximately 1 after 30 min. In the human brain, radioactivity in the cerebellum, cortex, and white matter reached a maximum within 5 min showing a cortex:white matter ratio of 1.6. The activity in the cortex declined to yield a ratio of 1 within 30 min. Of the delivered dose, 20% penetrated into the brain.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1600599     DOI: 10.1007/bf00686397

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  24 in total

1.  High-dose busulfan and myoclonic epilepsy.

Authors:  R W Martell; C Sher; P Jacobs; F Monteagudo
Journal:  Ann Intern Med       Date:  1987-01       Impact factor: 25.391

2.  11C-labeling of busulphan.

Authors:  M Hassan; J O Thorell; N Warne; S Stone-Elander
Journal:  Int J Rad Appl Instrum A       Date:  1991

3.  Preparative regimens for marrow transplantation containing busulphan are associated with haemorrhagic cystitis and hepatic veno-occlusive disease but a short duration of leucopenia and little oro-pharyngeal mucositis.

Authors:  K Atkinson; J Biggs; G Noble; M Ashby; A Concannon; A Dodds
Journal:  Bone Marrow Transplant       Date:  1987-12       Impact factor: 5.483

4.  Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study.

Authors:  G Vassal; A Deroussent; O Hartmann; D Challine; E Benhamou; D Valteau-Couanet; L Brugières; C Kalifa; A Gouyette; J Lemerle
Journal:  Cancer Res       Date:  1990-10-01       Impact factor: 12.701

5.  Performance study of the PC-384 positron camera system for emission tomography of the brain.

Authors:  J Litton; M Bergström; L Eriksson; C Bohm; G Blomqvist; M Kesselberg
Journal:  J Comput Assist Tomogr       Date:  1984-02       Impact factor: 1.826

6.  Determination of object contour from projections for attenuation correction in cranial positron emission tomography.

Authors:  M Bergström; J Litton; L Eriksson; C Bohm; G Blomqvist
Journal:  J Comput Assist Tomogr       Date:  1982-04       Impact factor: 1.826

7.  Glutathione and glutathione-S-transferases in the normal and diseased human liver.

Authors:  C P Siegers; K H Bossen; M Younes; R Mahlke; D Oltmanns
Journal:  Pharmacol Res Commun       Date:  1982-01

8.  Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections.

Authors:  W R Shapiro; D F Young; B M Mehta
Journal:  N Engl J Med       Date:  1975-07-24       Impact factor: 91.245

9.  Haemorrhagic cystitis in bone marrow transplantation patients: possible increased risk associated with prior busulphan therapy.

Authors:  A E Thomas; J Patterson; H G Prentice; M K Brenner; M Ganczakowski; J F Hancock; J K Pattinson; H A Blacklock; J P Hopewell
Journal:  Bone Marrow Transplant       Date:  1987-04       Impact factor: 5.483

10.  Urinary metabolites of busulfan in the rat.

Authors:  M Hassan; H Ehrsson
Journal:  Drug Metab Dispos       Date:  1987 May-Jun       Impact factor: 3.922

View more
  9 in total

1.  Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis.

Authors:  Janka Reimer; Sandra Bien; Sabine Ameling; Elke Hammer; Uwe Völker; Georg Hempel; Joachim Boos; Heyo K Kroemer; Christoph A Ritter
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

2.  Busulfan as a myelosuppressive agent for generating stable high-level bone marrow chimerism in mice.

Authors:  Kyle Peake; John Manning; Coral-Ann Lewis; Christine Barr; Fabio Rossi; Charles Krieger
Journal:  J Vis Exp       Date:  2015-04-01       Impact factor: 1.355

Review 3.  The role of busulfan in bone marrow transplantation.

Authors:  M Hassan
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

4.  Busulfan conditioning enhances engraftment of hematopoietic donor-derived cells in the brain compared with irradiation.

Authors:  Fiona L Wilkinson; Ana Sergijenko; Kia J Langford-Smith; Marcela Malinowska; Rob F Wynn; Brian W Bigger
Journal:  Mol Ther       Date:  2013-02-19       Impact factor: 11.454

5.  Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.

Authors:  M Hassan; G Oberg; M Björkholm; I Wallin; M Lindgren
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.

Authors:  Yi-Bin Chen; Tracy Batchelor; Shuli Li; Ephraim Hochberg; Mark Brezina; Sooae Jones; Candice Del Rio; Morgan Curtis; Karen K Ballen; Jeffrey Barnes; Andrew S Chi; Jorg Dietrich; Jessica Driscoll; Elizabeth R Gertsner; Fred Hochberg; Ann S LaCasce; Steven L McAfee; Thomas R Spitzer; Lakshmi Nayak; Philippe Armand
Journal:  Cancer       Date:  2014-09-09       Impact factor: 6.860

7.  Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations.

Authors:  I Boland; G Vassal; J Morizet; M J Terrier-Lacombe; D Valteau-Couanet; C Kalifa; O Hartmann; A Gouyette
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

8.  Biodistribution of biodegradable polymeric nano-carriers loaded with busulphan and designed for multimodal imaging.

Authors:  Heba Asem; Ying Zhao; Fei Ye; Åsa Barrefelt; Manuchehr Abedi-Valugerdi; Ramy El-Sayed; Ibrahim El-Serafi; Khalid M Abu-Salah; Jörg Hamm; Mamoun Muhammed; Moustapha Hassan
Journal:  J Nanobiotechnology       Date:  2016-12-19       Impact factor: 10.435

9.  Efficacy and Safety of Autologous Stem-Cell Transplantation as Part of First-Line Treatment for Newly Diagnosed Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis.

Authors:  Jing Liu; Jiayuan Guo; Xuefei Sun; Yuanbo Liu; Chunji Gao
Journal:  Front Oncol       Date:  2022-01-12       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.